Rezolute, Inc. Overview
Pro stress-test →Rezolute is a late-stage rare disease company focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody in Phase 3 clinical trial for treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for hypoglycemia and tumor hyperinsulinism.
Strategic Profile
Pro stress-test →The Phase 3 sunRIZE study did not meet its primary or key secondary endpoints, though some biomarker and CGM signals were observed. The company is pursuing FDA regulatory pathway discussions and has an ongoing Phase 3 tumor hyperinsulinism (upLIFT) study with topline data expected in H2 2026, positioning itself in the ultra-rare metabolic disease treatment space.
Competitive Landscape
Pro stress-test →Rezolute competes in the ultra-rare metabolic disease space with limited direct competitors given the niche nature of congenital and tumor hyperinsulinism. The company is a clinical-stage developer without approved medicines, positioning itself against potential future therapies from larger pharma and biotech firms entering this space.
Industry Context
Rezolute, Inc. operates in Biopharmaceutical - Rare Disease/Metabolic Disorders.
Key facts
Founded: 2010 · Headquarters: Redwood City, CA · Employees: 64 · Revenue: $0.00B · Market cap: $178.0M